Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children 10-16 With Chronic Kidney Disease (CKD)
Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 Years With Moderate to Severe Chronic Kidney Disease
Status: Enrolling
Updated:  1/5/2014
Clinical Research Facility
mi
from
Madison, WI
Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children 10-16 With Chronic Kidney Disease (CKD)
Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 Years With Moderate to Severe Chronic Kidney Disease
Status: Enrolling
Updated: 1/5/2014
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children 10-16 With Chronic Kidney Disease (CKD)
Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 Years With Moderate to Severe Chronic Kidney Disease
Status: Enrolling
Updated:  1/5/2014
Clinical Research Facility
mi
from
Milwaukee, WI
Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children 10-16 With Chronic Kidney Disease (CKD)
Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 Years With Moderate to Severe Chronic Kidney Disease
Status: Enrolling
Updated: 1/5/2014
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Kidney and Periodontal Disease Study
Kidney and Periodontal Disease Study
Status: Enrolling
Updated:  1/17/2014
San Francisco General Hospital
mi
from
San Francisco, CA
Kidney and Periodontal Disease Study
Kidney and Periodontal Disease Study
Status: Enrolling
Updated: 1/17/2014
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)
Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)
Status: Enrolling
Updated:  1/22/2014
Baptist Hospital of Miami, Baptist Cardiac and Vascular Institute
mi
from
Miami, FL
Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)
Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)
Status: Enrolling
Updated: 1/22/2014
Baptist Hospital of Miami, Baptist Cardiac and Vascular Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Status: Enrolling
Updated:  1/23/2014
Clinical Research Facility
mi
from
Miami, FL
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Status: Enrolling
Updated: 1/23/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study
Efficacy and Safety of the Dietary Approaches to Stop Hypertension (DASH) Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study
Status: Enrolling
Updated:  2/7/2014
Stedman Nutrition and Metabolism Center, Center for Living
mi
from
Durham, NC
Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study
Efficacy and Safety of the Dietary Approaches to Stop Hypertension (DASH) Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study
Status: Enrolling
Updated: 2/7/2014
Stedman Nutrition and Metabolism Center, Center for Living
mi
from
Durham, NC
Click here to add this to my saved trials
Desensitization Protocol for Deceased Donor List
Desensitization Protocol for Deceased Donor List
Status: Enrolling
Updated:  2/8/2014
University of Miami
mi
from
Miami, FL
Desensitization Protocol for Deceased Donor List
Desensitization Protocol for Deceased Donor List
Status: Enrolling
Updated: 2/8/2014
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Los Angeles, CA
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Palo Alto, CA
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
San Diego, CA
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
San Francisco, CA
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
San Francisco, CA
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Stanford, CA
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Aurora, CO
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Chicago, IL
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
St. Louis, MO
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
St. Louis, MO
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
New York, NY
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
New York, NY
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
New York, NY
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Portland, OR
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Dallas, TX
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Dallas, TX
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated:  2/12/2014
Pfizer Investigational Site
mi
from
Milwaukee, WI
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Status: Enrolling
Updated: 2/12/2014
Pfizer Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Sorbent Treatment Prescriptions Pilot Study
Hemodialysis With the 2008 Sorbent System: A Pilot Evaluation of Different Treatment Prescriptions
Status: Enrolling
Updated:  2/18/2014
Yorkville Dialysis Center
mi
from
New York, NY
Sorbent Treatment Prescriptions Pilot Study
Hemodialysis With the 2008 Sorbent System: A Pilot Evaluation of Different Treatment Prescriptions
Status: Enrolling
Updated: 2/18/2014
Yorkville Dialysis Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Tucson, AZ
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Lancaster, CA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Lancaster, CA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
San Diego, CA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Torrance, CA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Lakewood, CO
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Lakewood, CO
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Jacksonville, FL
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Miami, FL
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Tampa, FL
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Augusta, GA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Honolulu, HI
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Meridian, ID
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Gurnee, IL
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Gurnee, IL
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Peoria, IL
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Peoria, IL
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Evansville, IN
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Topeka, KA
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Rockville, MD
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Ann Arbor, MI
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Detroit, MI
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Pontiac, MI
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Pontiac, MI
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Springfield, MO
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Springfield, MO
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Billings, MT
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Nashua, NH
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Nashua, NH
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
Albany, NY
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated:  2/27/2014
Clinical Research Facility
mi
from
New York, NY
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease
Status: Enrolling
Updated: 2/27/2014
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials